10 research outputs found
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
Background: Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly due to concerns about the risk of progressive multifocal leukoencephalopathy. However, NTZ interruption may result in recrudescence of disease activity. Objective: The objective of this study was to summarize the available evidence about NTZ discontinuation and to identify which patients will experience post-NTZ disease reactivation through meta-analysis of existing literature data. Methods: PubMed was searched for articles reporting the effects of NTZ withdrawal in adult patients (⩾18 years) with relapsing–remitting multiple sclerosis (RRMS). Definition of disease activity following NTZ discontinuation, proportion of patients who experienced post-NTZ disease reactivation, and timing to NTZ discontinuation to disease reactivation were systematically reviewed. A generic inverse variance with random effect was used to calculate the weighted effect of patients’ clinical characteristics on the risk of post-NTZ disease reactivation, defined as the occurrence of at least one relapse. Results: The original search identified 205 publications. Thirty-five articles were included in the systematic review. We found a high level of heterogeneity across studies in terms of sample size (10 to 1866 patients), baseline patient characteristics, follow up (1–24 months), outcome measures (clinical and/or radiological), and definition of post-NTZ disease reactivation or rebound. Clinical relapses were observed in 9–80% of patients and peaked at 4–7 months, whereas radiological disease activity was observed in 7–87% of patients starting at 6 weeks following NTZ discontinuation. The meta-analysis of six articles, yielding a total of 1183 patients, revealed that younger age, higher number of relapses and gadolinium-enhanced lesions before treatment start, and fewer NTZ infusions were associated with increased risk for post-NTZ disease reactivation ( p ⩽ 0.05). Conclusions: Results from the present review and meta-analysis can help to profile patients who are at greater risk of post-NTZ disease reactivation. However, potential reporting bias and variability in selected studies should be taken into account when interpreting our data
Recommended from our members
Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis.
PURPOSE OF REVIEW:This review presents a critical appraisal of the use of autologous hematopoietic cell transplant (AHCT) for the treatment of multiple sclerosis. We present the reader with a brief review on the AHCT procedure, its immunomodulatory mechanism of action in MS, the most recent evidence in support of its use in patients with relapsing-remitting multiple sclerosis (RRMS), as well as its cost considerations. RECENT FINDINGS:The first meta-analysis of clinical trials of AHCT for patients with MS demonstrated durable 5-year progression-free survival rates and low treatment-related mortality. Recently, the first randomized controlled phase III clinical trial demonstrated AHCT to be superior to best available therapy for a subset of patients with RRMS. This led to the American society for transplant and cellular therapies (ASTCT) to recommend AHCT "for patients with relapsing forms of MS who have prognostic factors that indicate a high risk of future disability." AHCT should be considered for patients with RRMS with evidence of clinical activity who have failed 2 lines of therapy or at least one highly active disease-modifying therapy
Beyond focal cortical lesions in MS: an in vivo quantitative and spatial imaging study at 7T
Objectives: Using quantitative T2* 7-tesla (7T) MRI as a marker of demyelination and iron loss, we
investigated, in patients with relapsing-remitting multiple sclerosis (RRMS) and secondary progressive
multiple sclerosis (SPMS), spatial and tissue intrinsic characteristics of cortical lesion(s)
(CL) types, and structural integrity of perilesional normal-appearing cortical gray matter (NACGM)
as a function of distance from lesions.
Methods: Patients with MS (18 RRMS, 11 SPMS), showing at least 2 CL, underwent 7T T2*
imaging to obtain (1) magnitude images for segmenting focal intracortical lesion(s) (ICL) and
leukocortical lesion(s) (LCL), and (2) cortical T2* maps. Anatomical scans were collected at 3T
for cortical surface reconstruction using FreeSurfer. Seventeen age-matched healthy participants
served as controls.
Results: ICL were predominantly located in sulci of frontal, parietal, and cingulate cortex; LCL distribution
was more random. In MS, T2* was higher in both ICL and LCL, indicating myelin and iron
loss, than in NACGM (p , 0.00003) irrespective of CL subtype and MS phenotype. T2* was
increased in perilesional cortex, tapering away from CL toward NACGM, the wider changes being
for LCL in SPMS. NACGM T2* was higher in SPMS relative to RRMS (p 5 0.006) and healthy
cortex (p 5 0.02).
Conclusions: CL had the same degree of demyelination and iron loss regardless of lesion subtype
and disease stage. Cortical damage expanded beyond visible CL, close to lesions in RRMS, and
more diffusely in SPMS. Evaluation of NACGM integrity, beyond focal CL, could represent a surrogate
marker of MS progression
The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI
Using quantitative T2* at 7 Tesla (T) magnetic resonance imaging, we investigated whether impairment in selective cognitive functions in multiple sclerosis (MS) can be explained by pathology in specific areas and/or layers of the cortex. Thirty-one MS patients underwent neuropsychological evaluation, acquisition of 7 T multi-echo T2* gradient-echo sequences, and 3 T anatomical images for cortical surfaces reconstruction. Seventeen age-matched healthy subjects served as controls. Cortical T2* maps were sampled at various depths throughout the cortex and juxtacortex. Relation between T2*, neuropsychological scores and a cognitive index (CI), calculated from a principal component analysis on the whole battery, was tested by a general linear model. Cognitive impairment correlated with T2* increase, independently from white matter lesions and cortical thickness, in cortical areas highly relevant for cognition belonging to the default-mode network (p < 0.05 corrected). Dysfunction in different cognitive functions correlated with longer T2* in selective cortical regions, most of which showed longer T2* relative to controls. For most tests, this association was strongest in deeper cortical layers. Executive dysfunction, however, was mainly related with pathology in juxtameningeal cortex. T2* explained up to 20% of the variance of the CI, independently of conventional imaging metrics (adjusted-R2: 52–67%, p < 5.10− 4). Location of pathology across the cortical width and mantle showed selective correlation with impairment in differing cognitive domains. These findings may guide studies at lower field strength designed to develop surrogate markers of cognitive impairment in MS
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging
We used a surface-based analysis of T2* relaxation rates at 7 T magnetic resonance imaging, which allows sampling quantitative
T2* throughout the cortical width, to map in vivo the spatial distribution of intracortical pathology in multiple sclerosis. Ultrahigh
resolution quantitative T2* maps were obtained in 10 subjects with clinically isolated syndrome/early multiple sclerosis (43
years disease duration), 18 subjects with relapsing-remitting multiple sclerosis (54 years disease duration), 13 subjects with
secondary progressive multiple sclerosis, and in 17 age-matched healthy controls. Quantitative T2* maps were registered to
anatomical cortical surfaces for sampling T2* at 25%, 50% and 75% depth from the pial surface. Differences in laminar quantitative
T2* between each patient group and controls were assessed using general linear model (P50.05 corrected for multiple
comparisons). In all 41 multiple sclerosis cases, we tested for associations between laminar quantitative T2*, neurological disability,
Multiple Sclerosis Severity Score, cortical thickness, and white matter lesions. In patients, we measured, T2* in intracortical lesions
and in the intracortical portion of leukocortical lesions visually detected on 7 T scans. Cortical lesional T2* was compared with
patients’ normal-appearing cortical grey matter T2* (paired t-test) and with mean cortical T2* in controls (linear regression using
age as nuisance factor). Subjects with multiple sclerosis exhibited relative to controls, independent from cortical thickness, significantly
increased T2*, consistent with cortical myelin and iron loss. In early disease, T2* changes were focal and mainly confined at
25% depth, and in cortical sulci. In later disease stages T2* changes involved deeper cortical laminae, multiple cortical areas and
gyri. In patients, T2* in intracortical and leukocortical lesions was increased compared with normal-appearing cortical grey matter
(P51010 and P5107), and mean cortical T2* in controls (P5105 and P5106). In secondary progressive multiple
sclerosis, T2* in normal-appearing cortical grey matter was significantly increased relative to controls (P50.001). Laminar T2*
changes may, thus, result from cortical pathology within and outside focal cortical lesions. Neurological disability and Multiple
Sclerosis Severity Score correlated each with the degree of laminar quantitative T2* changes, independently from white matter
lesions, the greatest association being at 25% depth, while they did not correlate with cortical thickness and volume. These findings
demonstrate a gradient in the expression of cortical pathology throughout stages of multiple sclerosis, which was associated with
worse disability and provides in vivo evidence for the existence of a cortical pathological process driven from the pial surface
Is the relationship between cortical and white matter pathologic changes in multiple sclerosis spatially specific? A multimodal 7-T and 3-T MR imaging study with surface and tract-based analysis
Purpose: To investigate in vivo the spatial specificity of the interdependence between intracortical and white matter (WM) pathologic changes as function of cortical depth and distance from the cortex in multiple sclerosis (MS), and their independent contribution to physical and cognitive disability. Materials and Methods: This study was institutional review board–approved and participants gave written informed consent. In 34 MS patients and 17 age-matched control participants, 7-T quantitative T2* maps, 3-T T1-weighted anatomic images for cortical surface reconstruction, and 3-T diffusion tensor images (DTI) were obtained. Cortical quantitative T2* maps were sampled at 25%, 50%, 75% depth from pial surface. Tracts of interest were reconstructed by using probabilistic tractography. The relationship between DTI metrics voxelwise of the tracts and cortical integrity in the projection cortex was tested by using multilinear regression models. Results: In MS, DTI abnormal findings along tracts correlated with quantitative T2* changes (suggestive of iron and myelin loss) at each depth of the cortical projection area (P , .01, corrected). This association, however, was not spatially specific because abnormal findings in WM tracts also related to cortical pathologic changes outside of the projection cortex of the tract (P , .001). Expanded Disability Status Scale pyramidal score was predicted by axial diffusivity along the corticospinal tract (b = 4.6 3 103; P , .001), Symbol Digit Modalities Test score by radial diffusivity along the cingulum (b = 24.3 3 104; P , .01), and T2* in the cingulum cortical projection at 25% depth (b = 21.7; P , .05). Conclusion: Intracortical and WM injury are concomitant pathologic
processes in MS, which are not uniquely distributed according to a tract-cortex–specific pattern; their association may reflect a common stage-dependent mechanism
Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression
In multiple sclerosis, individual lesion-type patterns on magnetic resonance imaging might be valuable for predicting clinical outcome and monitoring treatment effects. Neuropathological and imaging studies consistently show that cortical lesions contribute to disease progression. The presence of chronic active white matter lesions harbouring a paramagnetic rim on susceptibility-weighted magnetic resonance imaging has also been associated with an aggressive form of multiple sclerosis. It is, however, still uncertain how these two types of lesions relate to each other, or which one plays a greater role in disability progression. In this prospective, longitudinal study in 100 multiple sclerosis patients (74 relapsing-remitting, 26 secondary progressive), we used ultra-high field 7-T susceptibility imaging to characterize cortical and rim lesion presence and evolution. Clinical evaluations were obtained over a mean period of 3.2 years in 71 patients, 46 of which had a follow-up magnetic resonance imaging. At baseline, cortical and rim lesions were identified in 96% and 63% of patients, respectively. Rim lesion prevalence was similar across disease stages. Patients with rim lesions had higher cortical and overall white matter lesion load than subjects without rim lesions (P = 0.018-0.05). Altogether, cortical lesions increased by both count and volume (P = 0.004) over time, while rim lesions expanded their volume (P = 0.023) whilst lacking new rim lesions; rimless white matter lesions increased their count but decreased their volume (P = 0.016). We used a modern machine learning algorithm based on extreme gradient boosting techniques to assess the cumulative power as well as the individual importance of cortical and rim lesion types in predicting disease stage and disability progression, alongside with more traditional imaging markers. The most influential imaging features that discriminated between multiple sclerosis stages (area under the curve +/- standard deviation = 0.82 +/- 0.08) included, as expected
The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7Â T MRI
Using quantitative T2* at 7Â Tesla (T) magnetic resonance imaging, we investigated whether impairment in selective cognitive functions in multiple sclerosis (MS) can be explained by pathology in specific areas and/or layers of the cortex.
Thirty-one MS patients underwent neuropsychological evaluation, acquisition of 7Â T multi-echo T2* gradient-echo sequences, and 3Â T anatomical images for cortical surfaces reconstruction. Seventeen age-matched healthy subjects served as controls.
Cortical T2* maps were sampled at various depths throughout the cortex and juxtacortex. Relation between T2*, neuropsychological scores and a cognitive index (CI), calculated from a principal component analysis on the whole battery, was tested by a general linear model.
Cognitive impairment correlated with T2* increase, independently from white matter lesions and cortical thickness, in cortical areas highly relevant for cognition belonging to the default-mode network (p < 0.05 corrected). Dysfunction in different cognitive functions correlated with longer T2* in selective cortical regions, most of which showed longer T2* relative to controls. For most tests, this association was strongest in deeper cortical layers. Executive dysfunction, however, was mainly related with pathology in juxtameningeal cortex. T2* explained up to 20% of the variance of the CI, independently of conventional imaging metrics (adjusted-R2: 52–67%, p < 5.10−4).
Location of pathology across the cortical width and mantle showed selective correlation with impairment in differing cognitive domains. These findings may guide studies at lower field strength designed to develop surrogate markers of cognitive impairment in MS